youtube_live
Q3 2026 earnings • released • EPS beat +26.81% • Revenue beat +60.98%
See resultschevron_right
ABCL:NASDAQ
AbCellera Biologics Inc
$11.49
arrow_downward
-1.12%(-0.13) 1D
$11.52
arrow_upward
+0.26% (+0.030)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$11.75
High
$11.83
Low
$11.06
Mkt. cap
3.75B
Avg. vol.
3.97M
Volume
2.68M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.48
Beta
1.59
Shares outstanding
326.62M
No. of employees
562
Open
$11.75
High
$11.83
Low
$11.06
Mkt. cap
3.75B
Avg. vol.
3.97M
Volume
2.68M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.48
Beta
1.59
Shares outstanding
326.62M
No. of employees
562
News stories
From web sources and news partners
Quantisnow
·
11 hours ago
AbCellera Biologics (ABCL) CFO Booth bought 8,600 shares for $97.4K at $11.33
Zacks
·
1 day ago
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
TradingView
·
2 days ago
ABCL: ABCL635’s phase II efficacy positions it for late-stage development next year
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth Care
Industry-
Websiteabcellera.com